A Phase 2 Study of Once-Weekly LY3298176 Compared With Placebo and Dulaglutide in Patients With Type 2 Diabetes Mellitus

Trial Profile

A Phase 2 Study of Once-Weekly LY3298176 Compared With Placebo and Dulaglutide in Patients With Type 2 Diabetes Mellitus

Recruiting
Phase of Trial: Phase II

Latest Information Update: 25 Jul 2017

At a glance

  • Drugs LY 3298176 (Primary) ; Dulaglutide
  • Indications Type 2 diabetes mellitus
  • Focus Therapeutic Use
  • Sponsors Eli Lilly
  • Most Recent Events

    • 01 Jun 2017 Planned End Date changed from 16 Apr 2018 to 29 May 2018.
    • 01 Jun 2017 Planned primary completion date changed from 16 Apr 2018 to 29 May 2018.
    • 01 Jun 2017 Status changed from not yet recruiting to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top